Changes in Cytokeratin 18 during Neoadjuvant Chemotherapy of Breast Cancer: A Prospective Study.
Breast carcinoma
Cytokeratin-18
M30 cytokeratin-18 peptide
M65 cytokeratin-18 peptide
Neoadjuvant therapy
Journal
Iranian journal of pathology
ISSN: 1735-5303
Titre abrégé: Iran J Pathol
Pays: Iran
ID NLM: 101515128
Informations de publication
Date de publication:
2020
2020
Historique:
received:
24
10
2019
accepted:
27
01
2020
entrez:
28
3
2020
pubmed:
28
3
2020
medline:
28
3
2020
Statut:
ppublish
Résumé
Prediction of response to neoadjuvant treatment is an important part of treatment of patients with breast cancer. This study aimed to assess changes in serum levels of Cytokeratin 18 during neoadjuvant chemotherapy in patients with locally advanced breast cancer and its association with neoadjuvant treatments. This research was performed on newly diagnosed breast cancer patients referred to Omid Radiotherapy Center and radiotherapy and oncology departments of Emam Reza and Ghaem hospitals, in Mashhad, Iran. Serum levels of M30 and M65 fragments of Cytokeratin 18 were measured before and 24 hours after the first course of neoadjuvant chemotherapy. Changes in serum levels of Cytokeratin 18 and its fragments and their correlation with pathologic response were analyzed. Pre- and post-chemotherapy levels of M30 were respectively 223.9±18.94 and 250.7±23.92 U/L ( Our findings showed statistically insignificant changes in the level of Caspase-cleaved- (M30) and uncleaved- (M65) cytokeratin 18 fragments (apoptotic and necrotic indicators, respectively) during neoadjuvant chemotherapy in patients with breast cancer. There was no notable relationship between tumor-related factors and either baseline levels or serum changes of CK18 fragments. Also, there was no correlation between M30/M65 level and pathologic response to neoadjuvant chemotherapy.
Sections du résumé
BACKGROUND & OBJECTIVE
OBJECTIVE
Prediction of response to neoadjuvant treatment is an important part of treatment of patients with breast cancer. This study aimed to assess changes in serum levels of Cytokeratin 18 during neoadjuvant chemotherapy in patients with locally advanced breast cancer and its association with neoadjuvant treatments.
METHODS
METHODS
This research was performed on newly diagnosed breast cancer patients referred to Omid Radiotherapy Center and radiotherapy and oncology departments of Emam Reza and Ghaem hospitals, in Mashhad, Iran. Serum levels of M30 and M65 fragments of Cytokeratin 18 were measured before and 24 hours after the first course of neoadjuvant chemotherapy. Changes in serum levels of Cytokeratin 18 and its fragments and their correlation with pathologic response were analyzed.
RESULTS
RESULTS
Pre- and post-chemotherapy levels of M30 were respectively 223.9±18.94 and 250.7±23.92 U/L (
CONCLUSION
CONCLUSIONS
Our findings showed statistically insignificant changes in the level of Caspase-cleaved- (M30) and uncleaved- (M65) cytokeratin 18 fragments (apoptotic and necrotic indicators, respectively) during neoadjuvant chemotherapy in patients with breast cancer. There was no notable relationship between tumor-related factors and either baseline levels or serum changes of CK18 fragments. Also, there was no correlation between M30/M65 level and pathologic response to neoadjuvant chemotherapy.
Identifiants
pubmed: 32215027
doi: 10.30699/ijp.2020.116238.2261
pmc: PMC7081760
doi:
Types de publication
Journal Article
Langues
eng
Pagination
117-126Références
Cancer Metastasis Rev. 1996 Dec;15(4):445-71
pubmed: 9034603
Cancer Lett. 2013 Aug 9;336(1):140-8
pubmed: 23612068
CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
pubmed: 21296855
J Cell Biochem. 2019 May;120(5):6833-6840
pubmed: 30368889
Ann Surg Oncol. 2012 May;19(5):1508-16
pubmed: 22193884
Ann Surg Oncol. 2006 Nov;13(11):1443-9
pubmed: 17028770
Ann Oncol. 2018 Aug 1;29(8):1634-1657
pubmed: 30032243
Curr Pharm Des. 2018;24(39):4646-4651
pubmed: 30636576
Cancer Invest. 2006 Nov;24(7):669-76
pubmed: 17118776
BMC Cancer. 2014 Jun 03;14:394
pubmed: 24894702
Biomed Pharmacother. 2014 Oct;68(8):1135-40
pubmed: 25465151
J Cell Physiol. 2019 Jul;234(7):12080-12086
pubmed: 30569450
Breast Cancer Res. 2006;8(5):R60
pubmed: 17062129
Lung Cancer. 2007 Jun;56(3):399-404
pubmed: 17316892
Semin Oncol. 2001 Aug;28(4):389-99
pubmed: 11498832
Clin Cancer Res. 2007 Jun 1;13(11):3198-206
pubmed: 17545523
Breast. 2016 Aug;28:95-9
pubmed: 27262825
Ann Diagn Pathol. 2017 Jun;28:43-53
pubmed: 28648939
Clin Cancer Res. 1996 Nov;2(11):1879-85
pubmed: 9816144
Clin Cancer Res. 2004 Apr 15;10(8):2670-4
pubmed: 15102669
AJR Am J Roentgenol. 2017 Feb;208(2):290-299
pubmed: 27809573
Curr Probl Cancer. 2020 Feb;44(1):100497
pubmed: 31371034